Andy Trotti1, Qiang Zhang2, Søren M Bentzen3, Bahman Emami4, M Elizabeth Hammond5, Christopher U Jones6, William H Morrison7, Stephen M Sagar8, John A Ridge9, Karen K Fu10, K Kian Ang11. 1. Department of Radiation Oncology, University of South Florida H. Lee Moffittt Cancer Center, Tampa, Florida. Electronic address: andy.trotti@moffitt.org. 2. RTOG Statistical Center, Philadelphia, Pennsylvania. 3. Department of Human Oncology, University of Wisconsin School of Medicine, Madison, Wisconsin. 4. Department of Radiation Therapy, Loyola University Medical Center, Maywood, Illinois. 5. Department of Pathology, LDS Hospital, Salt Lake City, Utah. 6. Radiological Associates of Sacramento, Sacramento, California. 7. University of Texas MD Anderson Cancer Center, Houston, Texas. 8. McMaster University, Juravinski Cancer Centre, Hamilton, Ontario, Canada. 9. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 10. Department of Radiation Oncology, University of California (emeritus), San Francisco, California. 11. Department of Radiotherapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
PURPOSE: To compare hyperfractionation versus standard fractionation for T2N0 vocal cord carcinoma in a randomized controlled trial. METHODS AND MATERIALS: Patients with T2 vocal cord cancer were stratified by substage (T2a vs T2b) and randomly assigned to receive either hyperfractionation (HFX) to 79.2 Gy in 66 fractions of 1.2 Gy given twice a day, or standard fractionation (SFX) to 70 Gy in 35 fractions given once a day. The trial was designed to detect a 55% reduction in the local failure hazard rate with 80% statistical power. RESULTS:Between April 1996 and July 2003, a total of 250 patients were enrolled. Of 239 patients analyzable for outcomes, 94% were male, 83% had a Karnofsky performance status of 90-100, and 62% had T2a tumor. Median follow-up for all surviving patients was 7.9 years (range, 0.6-13.1 years). The 5-year local control (LC) rate was 8 points higher but not statistically significant (P=.14 for HFX [78%] vs SFX [70%]), corresponding to a 30% hazard rate reduction. The 5-year disease-free survival (DFS) was 49% versus 40% (P=.13) and overall survival (OS) was 72% versus 63% (P=.29). HFX was associated with higher rates of acute skin, mucosal, and laryngeal toxicity. Grade 3-4 late effects were similar with a 5-year cumulative incidence of 8.5% (3.4%-13.6%) after SFX and 8.5% (3.4%-13.5%) after HFX. CONCLUSIONS: The 5-year local control was modestly higher with HFX compared to SFX for T2 glottic carcinoma, but the difference was not statistically significant. These results are consistent with prior studies of hyperfractionation showing a benefit in local control. Substaging by T2a versus T2b carries prognostic value for DFS and OS. For cost and convenience reasons other altered fractionation schedules have been adopted in routine practice.
RCT Entities:
PURPOSE: To compare hyperfractionation versus standard fractionation for T2N0 vocal cord carcinoma in a randomized controlled trial. METHODS AND MATERIALS: Patients with T2 vocal cord cancer were stratified by substage (T2a vs T2b) and randomly assigned to receive either hyperfractionation (HFX) to 79.2 Gy in 66 fractions of 1.2 Gy given twice a day, or standard fractionation (SFX) to 70 Gy in 35 fractions given once a day. The trial was designed to detect a 55% reduction in the local failure hazard rate with 80% statistical power. RESULTS: Between April 1996 and July 2003, a total of 250 patients were enrolled. Of 239 patients analyzable for outcomes, 94% were male, 83% had a Karnofsky performance status of 90-100, and 62% had T2a tumor. Median follow-up for all surviving patients was 7.9 years (range, 0.6-13.1 years). The 5-year local control (LC) rate was 8 points higher but not statistically significant (P=.14 for HFX [78%] vs SFX [70%]), corresponding to a 30% hazard rate reduction. The 5-year disease-free survival (DFS) was 49% versus 40% (P=.13) and overall survival (OS) was 72% versus 63% (P=.29). HFX was associated with higher rates of acute skin, mucosal, and laryngeal toxicity. Grade 3-4 late effects were similar with a 5-year cumulative incidence of 8.5% (3.4%-13.6%) after SFX and 8.5% (3.4%-13.5%) after HFX. CONCLUSIONS: The 5-year local control was modestly higher with HFX compared to SFX for T2 glottic carcinoma, but the difference was not statistically significant. These results are consistent with prior studies of hyperfractionation showing a benefit in local control. Substaging by T2a versus T2b carries prognostic value for DFS and OS. For cost and convenience reasons other altered fractionation schedules have been adopted in routine practice.
Authors: Martin Canis; Alexios Martin; Friedrich Ihler; Hendrik A Wolff; Martina Kron; Christoph Matthias; Wolfgang Steiner Journal: Head Neck Date: 2013-09-02 Impact factor: 3.147
Authors: Jonathan J Beitler; Qiang Zhang; Karen K Fu; Andy Trotti; Sharon A Spencer; Christopher U Jones; Adam S Garden; George Shenouda; Jonathan Harris; Kian K Ang Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-07 Impact factor: 7.038
Authors: Jean Bourhis; Jens Overgaard; Hélène Audry; Kian K Ang; Michele Saunders; Jacques Bernier; Jean-Claude Horiot; Aurélie Le Maître; Thomas F Pajak; Michael G Poulsen; Brian O'Sullivan; Werner Dobrowsky; Andrzej Hliniak; Krzysztof Skladowski; John H Hay; Luiz H J Pinto; Carlo Fallai; Karen K Fu; Richard Sylvester; Jean-Pierre Pignon Journal: Lancet Date: 2006-09-02 Impact factor: 79.321
Authors: Bhishamjit S Chera; Robert J Amdur; Christopher G Morris; Jessica M Kirwan; William M Mendenhall Journal: Int J Radiat Oncol Biol Phys Date: 2010-02-12 Impact factor: 7.038
Authors: A Hliniak; B Gwiazdowska; Z Szutkowski; E Kraszewska; P Kukolowicz; A Jarzabski; B Sochacka; M Mazurkiewicz; K Paprota; W Oliskiewicz; O Zadrozna; P Milecki; M Kubiak; L Czopkiewicz; M Jagas; S Góźdź; A Wieczorek; A Woytowicz; B Cisowska; H Magdziarz; S Nowakowski; W Kośniewski; I Laskosz; A Serafin; E Gradoń Journal: Radiother Oncol Date: 2002-01 Impact factor: 6.280
Authors: Sung Ho Moon; Kwan Ho Cho; Eun Ji Chung; Chang Geol Lee; Kyu Chan Lee; Gyu-Young Chai; Ki Mun Kang; Jong Young Lee; Woong-Ki Chung; Woo Yoon Park; Jin Hee Kim Journal: Radiother Oncol Date: 2013-10-22 Impact factor: 6.280
Authors: Adam S Garden; Ken Forster; Pei-Fong Wong; William H Morrison; Naomi R Schechter; K Kian Ang Journal: Int J Radiat Oncol Biol Phys Date: 2003-02-01 Impact factor: 7.038
Authors: Mohamed Shelan; Lukas Anschuetz; Adrian D Schubert; Beat Bojaxhiu; Alan Dal Pra; Frank Behrensmeier; Daniel M Aebersold; Roland Giger; Olgun Elicin Journal: Strahlenther Onkol Date: 2017-05-04 Impact factor: 3.621
Authors: Qiang Zhang; Boris Freidlin; Edward L Korn; Susan Halabi; Sumithra Mandrekar; James J Dignam Journal: Clin Trials Date: 2016-09-22 Impact factor: 2.486
Authors: William A Stokes; Diana Abbott; Andy Phan; David Raben; Ryan M Lanning; Sana D Karam Journal: Int J Radiat Oncol Biol Phys Date: 2017-04-06 Impact factor: 7.038
Authors: Karine A Al Feghali; Bassem Y Youssef; Abdallah S R Mohamed; Lara Hilal; Blaine D Smith; Ibrahim Abu-Gheida; Georges Farha; G Brandon Gunn; Jack Phan; Jan Lewin; Apurva Thekdi; William H Morrison; Adam S Garden; Clifton David Fuller; David I Rosenthal Journal: Head Neck Date: 2020-06-02 Impact factor: 3.147
Authors: Bertrand Baujat; Jean Bourhis; Pierre Blanchard; Jens Overgaard; Kian K Ang; Michelle Saunders; Aurélie Le Maître; Jacques Bernier; Jean Claude Horiot; Emilie Maillard; Thomas F Pajak; Michael G Poulsen; Abderrahmane Bourredjem; Brian O'Sullivan; Werner Dobrowsky; Hliniak Andrzej; Krzystof Skladowski; John H Hay; Luiz Hj Pinto; Karen K Fu; Carlo Fallai; Richard Sylvester; Jean Pierre Pignon Journal: Cochrane Database Syst Rev Date: 2010-12-08